Cameron Turtle Eidos Therapeutics, Inc. (EIDX) insider trading activity

Cameron Turtle is Chief Business Officer of Eidos Therapeutics, Inc.. Currently has a direct ownership of 0 shares of EIDX, which is worth approximately $0. The most recent transaction as insider was on Jan 26, 2021, when has been sold 50,699 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Cameron Turtle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 26 2021	SELL Disposition due to a tender of shares in a change of control transaction	-	50,699 Reduced 100.0%	0 Common Stock
Dec 15 2020	SELL Open market or private sale	$2,936,777 $111.69 p/Share	26,294 Reduced 34.19%	50,621 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	$397,039 $15.1 p/Share	26,294 Added 25.48%	76,915 Common Stock
Nov 11 2020	SELL Bona fide gift	-	1,500 Reduced 2.88%	50,621 Common Stock
Nov 11 2020	SELL Open market or private sale	$999,179 $74.51 p/Share	13,410 Reduced 20.46%	52,121 Common Stock
Nov 02 2020	SELL Open market or private sale	$891,500 $71.32 p/Share	12,500 Reduced 16.02%	65,531 Common Stock
Nov 02 2020	BUY Exercise of conversion of derivative security	$113,250 $15.1 p/Share	7,500 Added 8.77%	78,031 Common Stock

Also insider at

BBIO

BridgeBio Pharma, Inc. Healthcare

Officer

AGLE

Aeglea BioTherapeutics, Inc. Healthcare

Chief Executive Officer

Cameron Turtle

Chief Business Officer

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EIDX shares.

Notify only if

Value

Insider Trading

Get notified when an Eidos Therapeutics, Inc. insider buys or sells EIDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Eidos Therapeutics, Inc.

Track Activities on EIDX

Account